| Literature DB >> 28138021 |
Rungtiwa Dangtakot1,2, Somchai Pinlaor3,4, Upsornsawan Itthitaetrakool5, Apisit Chaidee3,4, Chariya Chomvarin6,4, Arunnee Sangka2, Chotechana Wilailuckana2, Porntip Pinlaor7,4.
Abstract
Persistent infection with Opisthorchis viverrini causes hepatobiliary abnormalities, predisposing infected individuals to cholangiocarcinoma (CCA). In addition, Helicobacter pylori is highly prevalent in most countries and is a possible risk factor for CCA; however, its role in enhancing hepatobiliary abnormality is unclear. Here, we investigated the effects of coinfection with H. pylori and O. viverrini on hepatobiliary abnormality. Hamsters were divided into four groups: (i) normal, (ii) H. pylori infected (HP), (iii) O. viverrini infected (OV), and (iv) O. viverrini and H. pylori infected (OV+HP). At 6 months postinfection, PCR and immunohistochemistry were used to test for the presence of H. pylori in the stomach, gallbladder, and liver. In the liver, H. pylori was detected in the following order: OV+HP, 5 of 8 (62.5%); HP, 2 of 5 (40%); OV, 2 of 8 (25%). H. pylori was not detected in normal (control) liver tissues. Coinfection induced the most severe hepatobiliary abnormalities, including periductal fibrosis, cholangitis, and bile duct hyperplasia, leading to a significantly decreased survival rate of experimental animals. The greatest thickness of periductal fibrosis was associated with a significant increase in fibrogenesis markers (expression of alpha smooth muscle actin and transforming growth factor beta). Quantitative reverse transcription-PCR revealed that the highest expression levels of genes for proinflammatory cytokines (interleukin-1 [IL-1], IL-6, and tumor necrosis factor alpha) were also observed in the OV+HP group. These results suggest that coinfection with H. pylori and O. viverrini increased the severity of hepatobiliary abnormalities to a greater extent than either single infection did.Entities:
Keywords: Helicobacter pylori; Opisthorchis viverrini; cholangitis; hepatic inflammation; hepatobiliary disease; periductal fibrosis
Mesh:
Substances:
Year: 2017 PMID: 28138021 PMCID: PMC5364296 DOI: 10.1128/IAI.00009-17
Source DB: PubMed Journal: Infect Immun ISSN: 0019-9567 Impact factor: 3.441